Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Johann S. de Bono, Pasquale Rescigno et al.|European Urology|2019Cited by 464
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Núria Porta et al.|Cancer Discovery|2021Cited by 161
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Johann S. de Bono, Adam Sharp et al.|Clinical Cancer Research|2018Cited by 158
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Johann S. de Bono, Adam Sharp et al.|Nature|2023Cited by 119
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Johann S. de Bono, Nicolás Herranz et al.|European Urology|2020Cited by 118